期刊文献+

坦度螺酮与氯硝西泮治疗广泛性焦虑症的对照研究 被引量:12

A comparative study of tandospirone versus clonazepam in the treatment of generalized anxiety disorder
下载PDF
导出
摘要 目的了解坦度螺酮对广泛性焦虑症的治疗效果及不良反应。方法将符合CCMD-3广泛性焦虑症诊断标准的82例患者随机分为坦度螺酮组(41例)和氯硝西泮组(41例),均治疗6周,采用汉密顿焦虑量表(HAMA)和临床疗效总体量表(CGI)以及不良反应量表(TESS)评定疗效和不良反应。结果坦度螺酮和氯硝西泮对广泛性焦虑症均有显著疗效,两组间差异无显著性(P>0.05)。坦度螺酮组不良反应明显小于氯硝西泮组(P<0.01)。结论坦度螺酮治疗广泛性焦虑症安全有效,不良反应小。 Objective The aim of this study was to evaluate the therapeutic effect and side effects of tandospirone for treating the patients with generalized anxiety disorder. Methods A total of 82 patients meeting the criteria of CCMD-3 for generalized anxiety disorder were randomly assigned to tandospirone group(n=41)or clonazepam group(n=41) for 6 weeks of treatment. The efficacy and side effects were assessed with HAMA,CGI and TESS. Results Both drugs had marked efficacy in the treatment of generalized anxiety disorder, and there bad no significant difference between two groups. Tandospirone had significantly fewer side effects than clonazepam. Conclusion Tandospirone is safe and effective with slight side effects for treating patients with generalized anxiety disorder.
出处 《精神医学杂志》 2008年第1期27-28,共2页 Journal of Psychiatry
关键词 广泛性焦虑症 坦度螺酮 氯硝西泮 Generalized anxiety disorder Tandospirone Clonazepem
  • 相关文献

参考文献7

二级参考文献34

  • 1长田洋文 五岛雄一郎 铃木仁一 等.以循环系统心身疾病为对象的tandospirone(SM-3997)双盲对照临床试验--安慰剂对照,剂量对照,Ⅱ期临床晚期试验[J].基础和临床,1992,26:4311-4350.
  • 2村崎光邦 森温理 远骊俊吉 等.新型精神药物tandospirone(SM-3997)对各种神经症的疗效评价--与安定对照的Ⅲ期临床试验[J].临床评价,1992,20:295-329.
  • 3兼本成斌 五岛雄一郎 铃木仁一 等.新型精神药物SM-3997(tandospirone)的临床评价--以循环系统心身疾病为对象[J].基础和临床,1992,26:4227-4238.
  • 4木村政资 坂田利家 中川哲也 等.新型精神药物SM-3997(tandospirone)的临床评价--以心身疾病、抑郁症及神经症为对象的适应症及最佳剂量研究[J].基础和临床,1992,26:4239-4251.
  • 5清水宏志.Tandospironed的药理作用与5-HT1A的关系[J].基础和临床,1992,26:1697-1702.
  • 6筒井末春 齐藤敏二 桂戴作 等.以植物神经功能紊乱为对象的tandospirone(SM-3997)双盲对照临床试验--安慰剂对照,剂量对照,Ⅱ期临床晚期试验[J].基础和临床,1992,26:4289-4209.
  • 7筒井末春 齐藤敏二 桂戴作.新型精神药物tandospirone(SM-3997)的临床评价--以心身疾病和神经症为对象的Ⅱ期临床早期试验[J].基础和临床,1992,26:4252-4263.
  • 8[5]Murasaki M. Overview of serotonin 1A receptor selective agents in anxiety disorders - the developmental situation in Japan. Int Rev Psychiatry, 1995, 7:105~113
  • 9[6]Murasaki M, Miura S. Future of 5-HT1A receptor agonists (aryl-piperazine derivatives). Prog Neuro-Psychopharmacol &Biol Psychiatry, 1992, 16:833~845
  • 10[7]Matsumoto M, Yoshioka M. Possible involvment of serotonin receptors in anxiety disorders. Nippon Yakurigahu Zasshi, 2000,115 (Suppl.): S39~S44

共引文献144

同被引文献56

引证文献12

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部